(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...

AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...

AstraZeneca (LON:AZN) has had a rough month with its share price down 9.1%. But if you pay close attention, you ...

The first Christmas campaigns started in earnest last week, so it must be September. Murdoch makes money moves Rightmove ...

When “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn takeover of AstraZeneca, which would make ...

Sharma’s analysis would have taken into account AstraZeneca’s financial metrics, market dynamics, and potential for shareholder value creation, leading to his positive outlook on the company’s stock.

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

As a comparator, AstraZeneca used Imfinzi before surgery followed by no ... This effect was statistically significant, with a ...